

## Table of Contents

List of Figures	xiii-xviii
List of Tables	xix-xx
List of Abbreviations and Symbols	xxi-xxiv
Preface	xxv-xxvi
<b>1. Introduction</b>	<b>1-5</b>
<b>2. Literature review</b>	<b>6-26</b>
2.1. Diabetes mellitus (DM)	6
2.2. Types of DM	6
2.3. Pathophysiology of diabetes	7
2.3.1. Pathogenesis of Type 1 diabetes (T1D)	8
2.3.2. Pathogenesis of Type 2 diabetes (T2D)	8
2.4. The management paradigm for T2D	13
2.5. Epidemiology of diabetes	14
2.6. Complications of diabetes	15
2.7. Diabetic nephropathy (DN)	16
2.8. Epidemiology of DN	16
2.9. Pathological stages of DN	17
2.10. Pathophysiology of DN	18
2.10.1. Metabolic factors involved in DN pathogenesis	18
2.11. Tetramethylpyrazine (TMP)	20
2.11.1. Source and history	20
2.11.2. Therapeutic activity of TMP in various diseases	21
2.12. Role of PI3K/Akt/GLUT-4 signalling in insulin-mediated glucose uptake and amelioration of insulin resistance	23
2.12.1. Insulin signalling pathway	23

2.12.2.	The PI3K/AKT pathway	24
2.13.	Role of Akt signalling in the amelioration of renal apoptosis in DN	25
<b>3.</b>	<b>Objectives and Plan of work</b>	<b>27-29</b>
3.1.	Objectives	27
3.2.	Detailed research plan	27
<b>4.</b>	<b>Materials and Methods</b>	<b>30-49</b>
4.1.	Drugs, chemicals and antibodies	30
4.2.	Equipment and software	32
4.3.	Experimental animals	34
4.4.	Induction of T2D	34
4.4.1.	Induction of T2D in rats through the HFD-STZ model (for experiments related to the objective I)	34
4.4.2.	Induction of T2D in rats through the STZ-NCT model (for experiments related to the objective II)	35
4.5.	Experimental design	36
4.5.1.	Study design for objective I	36
4.5.2.	Study design for objective II	37
4.6.	Experimental procedure	37
4.6.1.	Study procedure for objective I	37
4.6.2.	Study procedure for objective II	38
4.7.	Biochemical estimations	39
4.7.1.	Estimation of lipid profile and glycosylated haemoglobin content	39
4.7.2.	Estimation of pro-inflammatory cytokines in serum	39
4.7.3.	Western blot analysis	40
4.7.4.	Real-time polymerase chain reaction (RT-PCR)	43
4.7.5.	Evaluation of oxidative stress and renal biochemical markers	47

4.7.6.	Histopathological examination	47
4.8.	Statistical Analysis	49
<b>5.</b>	<b>Results</b>	<b>50-83</b>
5.1.	Objective I results	50
5.1.1.	Effect of TMP treatment on body weight and FBG level of diabetic rats	50
5.1.2.	Effect of TMP treatment on FSI level, HOMA-IR and HOMA-B (%) of diabetic rats	52
5.1.3.	Effect of TMP treatment on the level of blood glucose in OGTT and ITT in diabetic rats	54
5.1.4.	Effect of TMP treatment on the level of glycosylated haemoglobin (HbA1c) in diabetic rats	55
5.1.5.	Effect of TMP treatment on serum lipid profile in diabetic rats	56
5.1.6.	Effect of TMP treatment on the level of pro-inflammatory cytokines in diabetic rats	59
5.1.7.	Western blotting analysis	60
5.1.8.	Confirmation of TMP mediated PI3K/Akt/GLUT-4 signalling through gene expression analysis by RT-PCR	64
5.2.	Objective II results	66
5.2.1.	The effect of TMP treatment on body weight, FBG, FSI, OGTT, HbA1c and lipid profile in diabetic rats	66
5.2.2.	Effect of TMP treatment on the oxidative stress parameters in kidney and serum of diabetic rats	72
5.2.3.	Effect of TMP treatment on renal biochemical markers in diabetic rats	75
5.2.4.	Effect of TMP treatment on renal morphology of diabetic rats	76
5.2.5.	Effect of TMP treatment on the expression of Akt signalling pathway proteins in the kidney tissue of diabetic rats	80
<b>6.</b>	<b>Discussion</b>	<b>84-93</b>
6.1.	Objective I discussion	84

6.2.	Objective II discussion	89
<b>7.</b>	<b>Summary</b>	<b>94-95</b>
<b>8.</b>	<b>Conclusion</b>	<b>96</b>
<b>9.</b>	<b>References</b>	<b>97-108</b>
<b>10.</b>	<b>List of Publications</b>	<b>109-110</b>